Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc., a pioneering…
Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has announced that the U.S. Food and Drug Administration (FDA) has…
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has announced the appointment of Alan Colowick, M.D., M.P.H., to its…
Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium Ferring Pharmaceuticals recently announced that three abstracts showcasing ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU),…
Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders, has announced the favorable outcome of…
TheraSyn Bio & Rubix LS Launch Project Panacea A Revolutionary Topical Breast Cancer Treatment Breast cancer remains one of the most prevalent and life-altering diseases affecting millions worldwide. Traditional treatment approaches, including chemotherapy, radiation, and surgical interventions, while effective, often…
Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), its proprietary gene therapy candidate for Fabry disease.…
Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus Communications (CACTUS), a global leader in science communication and technology.…
Broken String Biosciences Unveils Catalyst Program to Accelerate Gene Editing Therapy Development Broken String Biosciences a leader in advancing gene editing safety, has officially launched its Catalyst Early Access Program (EAP), an initiative designed to revolutionize the way gene-edited therapies…
Merck Begins Phase 3 Trial of Zilovertamab Vedotin for DLBCL Treatment DLBCL Treatment Merck known as MSD outside the United States and Canada, has officially announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial assessing the efficacy and…
Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Announce Exit from Pharmaceutics International, Inc. A consortium of investors, including Pharmascience Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience has successfully exited its equity stake in Pharmaceutics…
Marquis Cheryl Custard: A Pillar of Excellence in Research and Development Cheryl Custard has earned a prestigious spot in Marquis Who’s Who , a recognition reserved for individuals who demonstrate exceptional value in their respective fields. Selection into this esteemed…